Large Molecule Bioanalysis done differently

To help you achieve more.

We are a bioanalytical lab that has evolved the model for partnership in large molecule bioanalysis to benefit our customers and the patients they serve.

Services Delivered Scientist to Scientist

Our fully integrated GxP services are driven by your assay requirements and delivered by our veteran scientists – collaboratively, accurately, and on time.

biomarkers

Biomarkers

immunogenicity

Immunogenicity

pharmacokinetics

Pharmacokinetics (PK)

cell-based-assays

Cell-Based Assays

Solutions Enabled by World-Leading Expertise

Our team is comprised of recognized experts in effectively navigating complex and evolving opportunities for biotherapeutics innovation.

biosimilars

Biosimilars

gene-therapy

Gene Therapy

antibody-drug-conjugates

Antibody Drug Conjugates (ADCs)

immuno-oncology

Immuno-oncology

platform comparison guide

webinar title
NOW ACCESSIBLE ON-DEMAND

Clinical Relevance of (Unwanted Drug-Induced) Immune Responses

Webinar Co-Hosted with Bioanalysis Zone

Methods for the detection of drug-induced antibodies have become much more sensitive, but the question remains to be answered: are antibodies at this low concentration level clinically relevant? BioAgilytix’s Global CSO, Dr. Arno Kromminga addresses this subject and more.

Download Recording

The Bioagilytix Perspective

Explore the BioAgilytix way of thinking. Visit our Resource Center to learn more about our scientists’ expertise through case studies, blogs, industry articles and other scientific resources.

resource center

Visit Resource Center

usa europe labs

Advanced bioanalytical lab facilities to support all phases of large molecule global studies.

    LinkedIn Company Updates

  • 1 Day Agoview on linkedin

    BioAgilytix

    Biomarkers have the potential to inform the drug development process for both large and small molecule drugs. Learn more about our ability to carry out a wide variety of biomarker testing for both types of drugs: https://lnkd.in/egrVJ2Y

  • 1 Day Agoview on linkedin

    BioAgilytix

    A brand new type of cancer drug that acts as a ‘Trojan horse’ to kill tumor cells from within has shown promise in patients with six different cancer types. Read more about the Phase I/II global clinical trial results via PharmaTimes Media Ltd: https://lnkd.in/efBfMQD

  • 4 Days Agoview on linkedin

    BioAgilytix

    If you are attending the EIP Symposium in Lisbon next week, be sure to mark these scientific sessions in your calendar which will be presented by our Global CSO and leading immunogenicity expert Arno Kromminga. See full session details here: https://lnkd.in/guvrrmg

global map

Advancing Bioanalytical Excellence Internationally

Choose a Location to learn more about the premier bioanalytical services and solutions available at each of our advanced laboratories in the USA and Europe.